系统性红斑狼疮中糖皮质激素的应用。60 年来，它仍然更多的是一门艺术而非科学。
The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science.
机构信息
Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, The Netherlands.
出版信息
Autoimmun Rev. 2013 Mar;12(5):617-28. doi: 10.1016/j.autrev.2012.12.001. Epub 2012 Dec 8.
Systemic Lupus Erythematosus (SLE) is a clinically diverse, chronic autoimmune disease with inflammation in several organ systems. Its pathogenesis is complex, but includes many factors that can be influenced by glucocorticoids (GCs). Indeed, GCs constitute the corner-stone in SLE-treatment. However, guidelines for GC-treatment of the different disease manifestations are lacking and not every patient responds (sufficiently). The focus of this systematic review is to evaluate the differential glucocorticoid treatment of various SLE manifestations. In addition, some relevant mechanisms of glucocorticoid action as well as resistance are discussed.
系统性红斑狼疮（SLE）是一种临床表现多样、慢性自身免疫性疾病，可累及多个器官系统。其发病机制复杂，但包括许多受糖皮质激素（GCs）影响的因素。事实上，GCs 是 SLE 治疗的基石。然而，针对不同疾病表现的 GC 治疗指南尚缺乏，并且并非每位患者均有（充分）应答。本系统评价的重点是评估各种 SLE 表现的糖皮质激素治疗差异。此外，还讨论了糖皮质激素作用及耐药的一些相关机制。
Zotero 插件